An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.
Virology
; 511: 214-221, 2017 11.
Article
em En
| MEDLINE
| ID: mdl-28888111
ABSTRACT
The emergence of A(H7N9) virus strains with resistance to neuraminidase (NA) inhibitors highlights a critical need to discover new countermeasures for treatment of A(H7N9) virus-infected patients. We previously described an anti-NA mAb (3c10-3) that has prophylactic and therapeutic efficacy in mice lethally challenged with A(H7N9) virus when delivered intraperitoneally (i.p.). Here we show that intrananasal (i.n.) administration of 3c10-3 protects 100% of mice from mortality when treated 24h post-challenge and further characterize the protective efficacy of 3c10-3 using a nonlethal A(H7N9) challenge model. Administration of 3c10-3 i.p. 24h prior to challenge resulted in a significant decrease in viral lung titers and deep sequencing analysis indicated that treatment did not consistently select for viral variants in NA. Furthermore, prophylactic administration of 3c10-3 did not inhibit the development of protective immunity to subsequent homologous virus re-challenge. Taken together, 3c10-3 highlights the potential use of anti-NA mAb to mitigate influenza virus infection.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Orthomyxoviridae
/
Subtipo H7N9 do Vírus da Influenza A
/
Fatores Imunológicos
/
Anticorpos Monoclonais
/
Anticorpos Antivirais
/
Neuraminidase
Tipo de estudo:
Prognostic_studies
Limite:
Animals
Idioma:
En
Revista:
Virology
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Estados Unidos